Tapinarof

Tapinarof
Clinical data
Trade namesVtama, others
Other namesBenvitimod; GSK-2894512; (E)-3,5-Dihydroxy-4-isopropyl-trans-stilbene; 3,5-Dihydroxy-4-isopropylstilbene
License data
Routes of
administration		Topical
Drug classAryl hydrocarbon receptor agonist
ATC code
Legal status
Legal status
Identifiers
IUPAC name
  • 5-[(E)-2-Phenylethen-1-yl]-2-(propan-2-yl)benzene-1,3-diol
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC17H18O2
Molar mass254.329 g·mol−1
3D model (JSmol)
SMILES
  • CC(C)c1c(cc(cc1O)/C=C/c2ccccc2)O
InChI
  • InChI=1S/C17H18O2/c1-12(2)17-15(18)10-14(11-16(17)19)9-8-13-6-4-3-5-7-13/h3-12,18-19H,1-2H3/b9-8+
  • Key:ZISJNXNHJRQYJO-CMDGGOBGSA-N

Tapinarof, also known as benvitimod and sold under the brand name Vtama among others, is a medication used for the treatment of plaque psoriasis.[3] The medication is applied to the skin.[3] Besides its use in medicine, tapinarof is a naturally occurring compound found in bacterial symbionts of nematodes which has antibiotic properties.[4][5]

The medication acts as an aryl hydrocarbon receptor agonist.[3][6]

Tapinarof was approved for medical use in the United States in May 2022.[3][7][8][9] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.[10][11]

  1. ^ "Nduvra Product information". Health Canada. 4 April 2025. Retrieved 17 April 2025.
  2. ^ "Register of Innovative Drugs". Health Canada. Retrieved 9 May 2025.
  3. ^ a b c d e "Vtama- tapinarof cream". DailyMed. 23 May 2022. Archived from the original on 3 July 2022. Retrieved 19 June 2022.
  4. ^ Cite error: The named reference pmid18236486 was invoked but never defined (see the help page).
  5. ^ Cite error: The named reference pmid10930742 was invoked but never defined (see the help page).
  6. ^ Bissonnette R, Stein Gold L, Rubenstein DS, Tallman AM, Armstrong A (April 2021). "Tapinarof in the treatment of psoriasis: A review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor-modulating agent". Journal of the American Academy of Dermatology. 84 (4): 1059–1067. doi:10.1016/j.jaad.2020.10.085. PMID 33157177.
  7. ^ "Vtama: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 25 May 2022. Retrieved 24 May 2022.
  8. ^ "Vtama (Tapinarof) FDA Approval History".
  9. ^ "FDA Approves Dermavant's Vtama (tapinarof) cream, 1% for the Treatment of Plaque Psoriasis in Adults: First Topical Novel Chemical Entity Launched for Psoriasis in the U.S. in 25 Years". Dermavant Sciences (Press release). 24 May 2022. Archived from the original on 24 May 2022. Retrieved 24 May 2022.
  10. ^ "Advancing Health Through Innovation: New Drug Therapy Approvals 2022". U.S. Food and Drug Administration (FDA). 10 January 2023. Retrieved 22 January 2023. This article incorporates text from this source, which is in the public domain.
  11. ^ New Drug Therapy Approvals 2022 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2024. Archived from the original on 14 January 2024. Retrieved 14 January 2024. This article incorporates text from this source, which is in the public domain.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.